Form 8-K - Current report:
SEC Accession No. 0001664710-24-000094
Filing Date
2024-11-26
Accepted
2024-11-26 08:02:51
Documents
14
Period of Report
2024-11-26
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kros-20241126.htm   iXBRL 8-K 38500
2 EX-99.1 exhibit991112624pr.htm EX-99.1 9342
  Complete submission text file 0001664710-24-000094.txt   177131

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20241126.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20241126_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20241126_pre.xml EX-101.PRE 13046
16 EXTRACTED XBRL INSTANCE DOCUMENT kros-20241126_htm.xml XML 2823
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 811173868 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39264 | Film No.: 241498201
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)